Overview
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Eligibility
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be enrolled：
- Age range: 18 to 80 years old (inclusive), both male and female are acceptable；
- ECOG: 0-2；
- B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；
- At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；
Exclusion Criteria:
- A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；
- Previously received CD20-CD3 bispecific antibody treatment；
- Previous allogeneic hematopoietic stem cell transplantation；
- Previous solid organ transplantation；
- History of autoimmune diseases；
- Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)；
- Patients with a history of progressive multifocal leukoencephalopathy (PML)；
- A known or suspected history of CNS lymphoma (including primary or secondary)；
- There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；